Author

M. F. Mesleh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:protein folding & dynamics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. G. Reidenbach· 2 shared A. J. Leed· 2 shared E. V. Minikel· 2 shared J. A. Moroco· 2 shared S. L. Schreiber· 2 shared S. M. Vallabh· 2 shared A. I. Chan· 1 shared A. Ianari· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. G. Reidenbach

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction

D. C. McKinney, B. J. McMillan, M. Ranaghan, J. A. Moroco, M. Brousseau, Z. Mullin-Bernstein, M. O'Keefe, P. McCarren, M. F. Mesleh, K. M. Mulvaney, R. Singh, B. Bajrami, A. Skepner, D. E. Timm, D. Porter, , A. Ianari

The paper identifies a first-in-class inhibitor, BRD0639, that targets the PRMT5-PBM interaction, disrupting SAP binding and reducing substrate methylation in cancer cells.

bioRxiv · Feb 3, 2021 · PreprintCancer Biology

Multimodal small-molecule screening for human prion protein binders

A. G. Reidenbach, M. F. Mesleh, D. Casalena, S. M. Vallabh, J. L. Dahlin, A. J. Leed, A. I. Chan, D. L. Usanov, J. B. Yehl, C. T. Lemke, A. J. Campbell, R. N. Shah, O. K. Shrestha, J. R. Sacher, V. L. Rangel, , E. V. Minikel

This study screens for small-molecule binders of the human prion protein using multiple methods but finds only a weak binder with no therapeutic potential.

bioRxiv · Jun 18, 2020Biochemistry

Characterization of the prion protein binding properties of antisense oligonucleotides

A. G. Reidenbach, E. V. Minikel, H. T. Zhao, S. G. Guzman, A. J. Leed, M. F. Mesleh, H. B. Kordasiewicz, S. L. Schreiber, S. M. Vallabh

This study examines the binding and antiprion properties of antisense oligonucleotides (ASOs) targeting prion protein (PrP), finding that sequence-independent binding and aggregation occur, but only PrP-lowering ASOs are effective in vivo.

bioRxiv · Nov 7, 2019Biochemistry